Corcept Therapeutics Incorporated

NASDAQ:CORT

Biotechnology

Healthcare
$67.79 -2.34%

-$1.96 today

Market cap
$7.42B
Beta
0.50
P/E (TTM)
178.2
EPS (TTM)
$0.46
52W Low $28.66High $91.00

Volume 0.74M

Average 1.41M

CORT Total Liabilities

Everything the company owes to creditors and other parties.

Corcept Therapeutics IncorporatedNASDAQ: CORT

Total Liabilities · Q2 FY2026 · quarter ended Jun 2026

Total liabilities rises 10.2% from a year ago

Total liabilities stood at $182.93M at the end of Q2 FY2026, up 10.2% from a year earlier and up 3.4% from the prior quarter. Over 3 fiscal years it compounded at +32.3% a year.

Context

  • Total liabilities amounted to 20.6% of total assets at the end of Q2 FY2026, down 0.1 pp from a year earlier.
  • Total liabilities increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total liabilities keeps rising in the next quarterly balance sheet after a +10.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$182.93M+3.4% QoQ
Last fiscal yearDec 2025
$188.85M+17.3% YoY
Year agoJun 2025
$165.93M+10.2% since
Total Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.2%——
1 year+17.3%——
3-year CAGR+32.3%——
5-year CAGR——
10-year CAGR——

Total Liabilities history

USD · from the balance sheet

Latest · FY2025
188.85M USD
Year-over-year change
+17.3%
4-year CAGR
+40.9%

Total Liabilities vs competitors

How CORT compares with its peers on the latest reported figures

  • CORT's Jun 2026 total liabilities of $182.93M is the highest of the 3 companies compared; the peer median is $24.59M.
  • Its year-over-year change of +10.2% is the lowest of 3, against a peer median of +76.3%.
  • Total liabilities amounts to 20.6% of total assets for CORT, versus a peer median of 21.9%.
CORT Competitors Peer median
Total Liabilities for CORT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CORTCorcept Therapeutics IncorporatedJun 2026$182.93M +10.2%+32.3%20.6%
MBXMBX Biosciences, Inc. Common StockSep 2026$27.67M +120.7%-43.4%5.5%
SPRBSpruce Biosciences, Inc.Mar 2026$21.52M +31.8%-15.1%38.3%
Peer median (excluding CORT) $24.59M+76.3%-29.2%21.9%

Competitors are the stored peer set for CORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents77.62M66.33M135.55M127.67M120.5M
Short-term Investments145.92M365.34M232.67M255.67M251.66M
Net Receivables29.03M46.86M56.82M58.08M59.79M
Inventory4.99M6.1M7.73M12.41M12.87M
Other Current Assets8.92M14.62M25.86M8.29M12.16M
Total Current Assets266.46M499.25M458.64M471.6M485.46M
Property, Plant & Equipment (Net)1.52M1.78M315K8.01M6.47M
Goodwill00000
Intangible Assets00000
Long-term Investments112.28M4.95M57.18M219.83M160.27M
Tax Assets27.46M61.47M90.61M130.91M168.2M
Other Non-current Assets16.05M15.99M14.79M10.19M16.25M
Total Non-current Assets157.29M84.18M162.88M368.95M351.19M
Total Assets423.76M583.43M621.52M840.55M836.65M
Account Payables6.91M11.98M17.4M15.38M40.44M
Short-term Debt526K1.14M151K829K0
Tax Payables513K89K2.89M191K15.18M
Deferred Revenue000035.68M
Other Current Liabilities26.26M43.77M59.69M82.65M44.31M
Total Current Liabilities47.54M72.49M104.51M140.77M166.09M
Long-term Debt00005.02M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities409K9.1M10.31M14.08M17.74M
Total Non-current Liabilities409K9.1M10.31M20.19M22.76M
Total Liabilities47.95M81.59M114.81M160.96M188.85M
Common Stock127K131K133K136K140K
Retained Earnings194.97M296.39M402.53M543.74M643.39M
Accumulated OCI(227K)(869K)609K(217K)2.26M
Other Stockholders Equity00000
Minority Interest00000
Total Equity375.81M501.84M506.71M679.59M647.81M
Total Debt526K1.14M151K6.94M6.11M
Net Debt(77.09M)(65.19M)(135.4M)(120.73M)(114.39M)

Corcept Therapeutics Incorporated

NASDAQ:CORT

Intrinsic Alpha fair value

Locked

Current Price

$67.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.